Coherus Reports 89% Confirmed Response Rate in Esophageal Cancer Trial
Coherus Oncology reported an 89% confirmed response rate for a tagmokitug combination in a first-line esophageal cancer trial.
Related stories
Buyers Agree to Acquire 75% of B & S International for Up to HKD 289 Million
Buyers agreed to acquire a 75% stake in B & S International for up to HKD 289 million.
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
L3Harris Reports Record $53.2 Billion Backlog After $19.3 Billion in 3Q Orders
L3Harris received $19.3 billion in orders in the third quarter, bringing its backlog to a record $53.2 billion. The report adds to a series of record backlogs among defense contrac
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
Hilton Grand Vacations Shares Rise After Q3 Earnings Beat
Hilton Grand Vacations shares were up nearly 3% after the company reported third-quarter adjusted net income and revenue above consensus.
M impact | EQUITY | Oct 29, 2026, 02:10 PM UTC
Gulf stocks fall as Yemen and Iran war fears grow
M impact | EQUITY | Oct 29, 2026, 02:10 PM UTC
Blue Owl Capital Reports Quarterly Results
Blue Owl Capital reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 02:08 PM UTC
China Environmental Technology Plans Reorganization, Rights Issue to Raise HKD 190 Million
China Environmental Technology plans a capital reorganization and rights issue to raise up to HKD 190 million.
M impact | EQUITY | Oct 29, 2026, 02:08 PM UTC